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Abstract
Urinary excretion accounts for two-thirds of total elimination of uric acid and the remainder is excreted in feces. However,
the mechanism of extra-renal elimination is poorly understood. In the present study, we aimed to clarify the mechanism and
the extent of elimination of uric acid through liver and intestine using oxonate-treated rats and Caco-2 cells as a model of
human intestinal epithelium. In oxonate-treated rats, significant amounts of externally administered and endogenous uric
acid were recovered in the intestinal lumen, while biliary excretion was minimal. Accordingly, direct intestinal secretion was
thought to be a substantial contributor to extra-renal elimination of uric acid. Since human efflux transporter BCRP/ABCG2
accepts uric acid as a substrate and genetic polymorphism causing a decrease of BCRP activity is known to be associated
with hyperuricemia and gout, the contribution of rBcrp to intestinal secretion was examined. rBcrp was confirmed to
transport uric acid in a membrane vesicle study, and intestinal regional differences of expression of rBcrp mRNA were well
correlated with uric acid secretory activity into the intestinal lumen. Bcrp1 knockout mice exhibited significantly decreased
intestinal secretion and an increased plasma concentration of uric acid. Furthermore, a Bcrp inhibitor, elacridar, caused a
decrease of intestinal secretion of uric acid. In Caco-2 cells, uric acid showed a polarized flux from the basolateral to apical
side, and this flux was almost abolished in the presence of elacridar. These results demonstrate that BCRP contributes at
least in part to the intestinal excretion of uric acid as extra-renal elimination pathway in humans and rats.
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Introduction
Uric acid is a final product of purine nucleoside metabolism in
humans, and it is thought that its level is well controlled, mainly by
the balance between production in liver from purine nucleosides
and excretion into urine. Although its physiological role is poorly
understood, uric acid is thought not only to protect neuronal cells
due to its antioxidant activity, but also to play a role in maintaining
blood pressure [1,2]. It has been suggested that serum uric acid
(SUA) should be kept below 7 mg/dL to prevent hyperuricemia,
which is a clinically important risk factor for cardiovascular
diseases, chronic kidney disease and gout [3,4]. In addition, it is
known that several drugs in clinical use alter the level of SUA. For
example, angiotensin II receptor blockers such as losartan decrease
SUA level, while others increase it [5–8]. Salicylic acid causes an
increase in SUA level at low dose, but a decrease at high dose [9].
Accordingly, it is important to clarify the mechanisms that control
SUA level in order to understand the effects of drugs on uric acid
disposition and to find better ways of regulating SUA.
Uric acid handling in the kidney is very complex, involving
glomerular filtration, tubular reabsorption and secretion. The uric
acid transporters URAT1 and URATv1, located at the apical and
basolateral membranes of the proximal tubular cells, respectively,
are involved in renal reabsorption of uric acid [8–13]. On the other
hand, organic anion transporters including OAT1 [14], OAT2
[15,16], and OAT3 [17] at the basolateral membrane and other
transporters such as BCRP [18], NPT1 [19,20], NPT4 [21] and
MRP4 [22] at the apical membranes have been reported to be
involved in renal secretory transport of uric acid. Among them,
BCRP, NPT1 and NPT4 may make significant contributions to
renal handling of uric acid, because genetic polymorphisms of these
transportersareassociatedwithgoutand/orhyperuricemia[13,23].
Uric acid is also excreted from the body extra-renally, although
urinary excretion is predominant. Nevertheless, it has been
suggested that one-third to one-fourth of uric acid is recovered
in feces, indicating that biliary and/or intestinal secretion is an
important alternative pathway(s) of uric acid excretion [24,25].
However, there has been little mechanistic study on extra-renal
excretion of uric acid. Accordingly, the purpose of the present
study is to examine the mechanism(s) of uric acid excretion via
liver and intestine, focusing on hepatobiliary excretion and
intestinal secretion directly from blood into the lumen. Although
there are significant species difference in uric acid handling
between human and animals, transporters such as URAT1
[10,26,27], URATv1 [9,28], BCRP [29,30], OATs [14–17,31]
and NPTs [19–21,32] are expressed in both humans and rats.
However, rats exhibit a significantly lower SUA level than humans
owing to the contribution of uricase, which metabolizes uric acid
to allantoin as a final metabolic product of purine; this is different
from the situation in humans [33]. However, the uricase inhibitor
oxonate can decrease uricase activity in vivo [34]. Indeed, the SUA
level of oxonate-treated rats is increased to a level similar to that
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oxonate-treated rats to estimate the in vivo contribution of extra-
renal excretion of uric acid. Furthermore, Caco-2 cells, a well-
established model of human intestinal epithelial cells, were used as
a model to examine the human intestinal transport mechanism of
uric acid.
BCRP/ABCG2 (breast cancer resistance protein) is abundantly
expressed at the apical membrane of small intestinal epithelial cells
and in liver, and impaired BCRP function is associated with an
increase of SUA level [13]. Therefore, in the present study, we
focused on the contribution of BCRP to extra-renal clearance of
uric acid.
Results
In vivo excretion of externally administered [
14C]uric acid
in oxonate-treated rats
To estimate the relative contributions of excretory organs, we
measured the amounts of recovered radioactivity in urine, bile,
and intestinal luminal contents after intravenous administration of
[
14C]uric acid to oxonate-treated rats with bile duct ligation. The
results (percentage of dose) are shown in Table 1. Recoveries of
radioactivity in urine, bile, and intestinal luminal contents were
42.6, 0.68 and 8.90% of the dose, respectively. Accordingly,
urinary excretion was predominant and intestinal secretion was
also significant, while biliary excretion was very low. Although the
recovery of radioactivity was not complete, this could be explained
by retention of uric acid in the animal body and/or elimination via
other routes, such as in expelled air following metabolism in the
gut lumen [24]. A rough estimation based on the distribution
volume obtained from the plasma concentration-time curve and
plasma concentration at the time of measurement (2 hrs after
administration) suggested that 4.55% of the dose remained in the
body.
Secretion of endogenous uric acid into intestinal lumen
in oxonate-treated rats
Direct intestinal luminal secretion of endogenous uric acid was
evaluated in closed loops prepared separately from jejunum,
ileum, and colon of oxonate-treated rat (Fig. 1A). Uric acid was
directly secreted into the intestinal lumen at all segments, and
the values of intestinal secretion clearance were 0.4960.03,
1.5860.13, and 0.7660.17 mL/min/cm loop, respectively. Thus,
secretory clearance was in the order of ileum.colon.jejunum,
showing a clear regional difference.
Clearance of endogenous uric acid in oxonate-treated
rats
To compare the significance of direct secretion of uric acid from
blood to intestinal lumen with excretion into urine and bile,
endogenous uric acid clearance was determined in oxonate-treated
rats. As shown in Table 2A, urinary and biliary secretory
clearances were 0.50 and 0.02 mL/min, respectively, and
estimated total intestinal secretory clearance was 0.15 mL/min
based on the result of intestinal closed loop assay and intestinal
length (Table 2B), assuming that sections of the intestine that were
not measured exhibited equal clearance ability. Accordingly,
endogenous uric acid is also secreted in a significant amount via
the intestine, in the same way as externally administered [
14C]uric
acid (Table 1).
Identification of transporters involved in intestinal
secretion of uric acid
In order to identify the transporter molecules responsible for
intestinal secretion, transport of uric acid was directly evaluated
using membrane vesicles expressing human (h) and rat (r)
transporters hBCRP/rBcrp, hMRP2/rMrp2, and hMDR1. As
shown in Fig. 2A, in hBCRP- and rBcrp-expressing membrane
vesicles, uptake of uric acid in the presence of ATP was
Table 1. Recovery of [
14C] uric acid up to 120 min in oxonate-
treated rats.
Cp6Vd Urine Bile Intestine Bile+Intestine
4.55% 42.58% 0.68% 8.90% 9.58%
Recovery of [
14C]uric acid was determined in oxonate-treated rats after
intravenous administration of [
14C]uric acid (2 mCi/rat). Each value is the mean
of 4 to 9 measurements.
doi:10.1371/journal.pone.0030456.t001
Figure 1. Intestinal secretion of uric acid and regional
difference of Bcrp-mRNA expression. (A) Intestinal clearance of
uric acid at each of jejunum, ileum, and colon was determined by
means of the in situ intestinal closed loop method in oxonate-treated
rats in the absence (Control, open bars) and presence of elacridar
(10 mM, closed bars). Each bar indicates the mean 6 S.E.M. (n=3–8). An
asterisk (*) shows a significant difference from the control by Student’s
t-test (p,0.05), and double asterisks (**) show a significant difference
from ileum by Student’s t-test (p,0.05). (B) Level of BCRP mRNA
expression was determined in different region of intestine in oxonate-
treated rats, and then normalized to rat Gapdh. Each bar indicates the
mean 6 S.E.M. (n=6). Expression intensity in jejunum was individually
set to 1 and the intensities of ileum and colon were calculated relative
to it. An asterisk (*) shows a significant difference from ileum by
Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0030456.g001
Table 2. Clearance of endogenous uric acid in oxonate-
treated rats.
CLrenal CLbile CLintestine, estimated
0.5060.06 0.0260.002 0.15
Clearance of endogenous uric acid was measured in oxonate-treated rats. Urine,
bile and blood were collected up to 60 min and clearances were calculated by
dividing the amount excreted into each part by plasma AUC. Estimated
intestinal clearance was obtained as described in Materials and methods using
mean value of 5 individual measurements; 11862.52 cm for length for jejunum
and 15.760.33 cm for colon, respectively. Values indicate mean 6 S.E.M. (n=5).
doi:10.1371/journal.pone.0030456.t002
Intestinal Secretion of Uric Acid
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dependent uric acid uptake was observed with rMrp2, whereas
hMRP2and hMDR1wereinactive(Fig.2A).Theseresultsindicated
that uric acid is a substrate of rBcrp as well as hBCRP, and also, to a
minor extent,rMrp2. Subsequently, uricacid transportbyrBcrp was
further characterized. Saturation kinetics determined Km value and
Vmax as 12.560.77 mM and 67.364.21 nmol/5 min/mg protein,
respectively (Fig. 2B), although maximum concentration of uric acid
was 5 mM due to its low solubility. Low affinity of uric acid to rBcrp
which was characterized Km value of 12.5 mM, was very
comparable to that to hBCRP (Km=8.24 mM). Additionally, rBcrp
showed similar sensitivity to inhibitors with human BCRP as shown
in Fig. 2C.
To further determine if rBcrp contributes to intestinal secretion
of uric acid in rats, the influence of an inhibitor of hBCRP/rBcrp,
elaclidar [35], on uric acid uptake by rBcrp-expressing membrane
vesicles and intestinal secretion was examined by the in situ closed
ileal loop method. Because MDR1 does not transport uric acid,
altered transport of uric acid by elacridar, which is a strong
inhibitor for both MDR1 and BCRP, can be attributed to its
inhibitory effect on BCRP activity (Fig. 2A). The results are shown
in Figs. 1A and 3. In the presence of 10 mM elacridar, intestinal
secretory clearance was significantly decreased to 0.2760.04 (55%
of that in elacridar-untreated rats), 0.8260.12 (52%), and
0.2360.04 (30%) mL/min/cm loop in jejunum, ileum, and colon,
respectively (Table 1A). Interestingly, the regional difference of
intestinal secretion of uric acid tended to be associated with the
regional difference of mRNA expression levels of rBcrp, which was
most highly expressed in ileum (Fig. 1B). Furthermore, ileal
secretion of uric acid was inhibited to 53% and 34% of the control
in the presence of 0.1 and 10 mM elacridar, respectively (Fig. 3A).
Such an inhibitory effect of elacridar on ileal secretion of uric acid
was comparable to the effect of elacridar on uptake of uric acid by
membrane vesicles expressing rBcrp (Fig. 3B). Accordingly, rBcrp
is likely involved in uric acid secretion into the intestinal lumen.
Plasma uric acid and intestinal clearance in oxonate-
treated wild-type and Bcrp1 knockout mice
To examine the in vivo contribution of Bcrp1 to intestinal
secretion of uric acid, we measured endogenous uric acid in
plasma and evaluated its intestinal secretion by means of the
intestinal closed loop method in wild-type and Bcrp1-knockout
(Bcrp1
2/2) mice. As shown in Fig. 4A, plasma uric acid level was
much higher in Bcrp1
2/2 mice compared with wild-type mice
after oxonate treatment. In addition, the intestinal secretory
(0.6160.08 mL/min/cm) and renal clearance (16.061.77 mL/
min) of endogenous uric acid in Bcrp1
2/2 mice was significantly
lower than those in wild-type mice (1.0460.11 mL/min/cm, and
23.561.42 mL/min), respectively (Fig. 4B, C). Accordingly, it was
Figure 2. Uric acid transport by ABC transporters. (A) Uptake of [
14C]uric acid (20 mM) by vesicles expressing rat and human ABC transporters
was measured for 5 min at 37uC in the presence of 4 mM ATP (closed symbols) or AMP (open symbols). (B) Concentration dependency of and (C)
inhibition study for rBcrp-mediated uptake were studied. Inhibition study was performed in the absence or the presence of various inhibitors at
indicated concentrations. ATP-dependent uptake was obtained by subtracting uric acid uptake in the presence of AMP from that in the presence of
ATP, and the solid line was drawn by fitting based on non-linear least-squares regression analysis. Saturable transport of uric acid is also shown as an
Eadie-Hofstee plot. Each bar shows the mean 6 S.E.M. (n=3–6). An asterisk (*) shows a significant difference from (A and B) uric acid uptake in the
presence of AMP and (C) uric acid uptake in the absence of inhibitors by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0030456.g002
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secretion of uric acid.
Transcellular transport of uric acid in Caco-2 cells
To examine whether uric acid is secreted into gut lumen via
BCRP in humans, we studied transcellular transport of uric acid in
Caco-2 cells (Table 3). Secretory transport of uric acidacross Caco-2
cell monolayer was more than two-times greater than absorptive
transport (1.7360.11 vs. 0.8160.02 (610
26 cm/sec)), and such
polarized transport was significantly reduced in the presence of
elacridar (an inhibitor for both MDR1 and BCRP), Ko143 (a potent
inhibitor for BCRP) and MK571 (an inhibitor for MRPs), but not
verapamil (an inhibitor for MDR1). Accordingly, secretory transport
isthoughttobepredominantlyduetoBCRPinhumansbecauseuric
acid is unlikely a substrate of MDR1 and MRP2 (Fig. 2A).
Discussion
In this study, we investigated the contribution and molecular
mechanism of extra-renal elimination of uric acid. Since elevated
SUA has been reported to be associated with several diseases [3,4],
an understanding of the mechanism of uric acid disposition is
important in order to control SUA level. In humans, it is reported
that two-thirds of uric acid is excreted from kidney, while the rest
is recovered in feces [24]. In order to examine whether uric acid is
eliminated into intestinal lumen in rats, as it is in humans, we
firstly measured the extent of
14C recovery after intravenous
injection of [
14C]uric acid in oxonate-treated rats as a model
animal (Table 1). Uric acid was excreted into bile and intestinal
lumen in addition to urine, and most of the uric acid is secreted
directly into the intestinal lumen from blood, but not via the bile
ducts, as an extra-renal elimination pathway.
In order to confirm that intestinal luminal secretion is the major
extra-renal elimination pathway, we further evaluated intestinal
secretion of endogenous uric acid by means of the in situ intestinal
closed loop method in oxonate-treated rats (Table 2 and Fig. 1A).
The estimated total intestinal clearance was 0.15 mL/min
(Table 2), which was less than the urinary excretion clearance,
0.50 mL/min, but much larger than the biliary excretion
clearance, 0.02 mL/min. The relative contribution of extra-renal
excretion versus urinary excretion was comparable to that in the
case of
14C recovery in vivo (Table 1). This demonstrates a
significant contribution of intestinal secretion to extra-renal
elimination. Furthermore, endogenous uric acid was secreted
from blood directly into the intestinal lumen at all intestinal
segments, and the secretion at the ileum was about three- and two-
times greater than in jejunum and colon, respectively (Fig. 1A).
Then, we examined the molecular mechanism(s) of extra-renal
excretion of uric acid into intestinal lumen. Recently, Matsuo et al.
reported that genetic polymorphisms resulting in decreased BCRP
activity in humans are associated with an elevated SUA level,
resulting in an increased incidence of gout [36]. BCRP is
expressed in the apical membrane of proximal tubular cells in
humans [29], suggesting that it plays a role in urinary excretion of
uric acid. Since BCRP expression is much higher in the intestinal
epithelial cells and hepatocytes than in proximal tubular cells [37],
we compared the roles of BCRP and other transporters, MRP2
and MDR1, in extra-renal excretion of uric acid. These
transporters are well-characterized efflux transporters for xenobi-
otics and drugs in both intestine and liver. Uric acid was
transported by hBCRP/rBcrp and rMrp2, but not by hMRP2
or hMDR1 (Fig. 2). Since rMdr1a-expressing membrane vesicles
were not available, we examined bidirectional transport of uric
acid in LLC-PK1 cells expressing rMdr1a; however, no significant
difference between secretory and absorptive transport of uric acid
was observed (data not shown). Accordingly, it appears that uric
acid is a substrate of rBcrp, as well as hBCRP [18,36], and rBcrp
and hBCRP mediate uric acid secretion directly into the intestinal
lumen and via the bile duct. In further study, rBcrp-mediated
transport of uric acid was strongly inhibited by elacridar, Ko143
and estrone-3-sulfate, and moderately by benzbromarone,
MK571, rifampicin and cyclosporin A, respectively, but was not
affected by ketoprofen and salicylic acid (Fig. 2C). These results
are in agreement with the previous observations in hBCRP-
mediated transport [35,38,39]. Furthermore, Km value of uric acid
by rBcrp, 12.5 mM, was relatively close to that by hBCRP,
8.24 mM [36]. Accordingly, uric acid transport by BCRP shows
similar characteristics between human and rat. Because rMrp2 is
expressed in the bile canalicular membranes and intestinal apical
membrane [40,41], rMrp2, but not hMRP2, may also be involved
intestinal secretion of uric acid.
Since rBcrp was suggested to mediate uric acid secretion into
the intestinal lumen, the effect of the rBcrp inhibitor elacridar was
examined. Secretion of endogenous uric acid into the intestinal
lumen was significantly reduced in the presence of 10 mM
elacridar at all intestinal segments (Fig. 1A). Furthermore, the
inhibitory potential of elacridar on the uric acid uptake in rBcrp-
expressing vesicles was comparable to that on the intestinal
clearance of uric acid at rat ileum. Additionally, the mRNA
expression level of rBcrp in each segment was comparable with the
regional differences of intestinal secretion in the segments (Fig. 2).
These findings strongly indicated that Bcrp is at least involved in
the direct secretion of uric acid from intestines.
To obtain further evidence that Bcrp contributes to intestinal
secretion of uric acid, we employed intestinal closed loop assay of
oxonate-treated Bcrp
2/2 mice. Plasma uric acid was significantly
higher in Bcrp1
2/2 mice and ileal secretory clearance of uric
acid was significantly lower in Bcrp1
2/2 mice, as compared with
Figure 3. Effect of elacridar on intestinal secretion and rBcrp-
mediated uric acid uptake. (A) Intestinal clearance of uric acid at the
ileum was determined by means of the in situ intestinal closed loop
method in the absence (Control, white bar) and presence of 0.1 (gray
bar) and 10 mM elacridar (black bar). Each bar indicates the mean 6
S.E.M. (n=4–8). An asterisk (*) shows a significant difference from the
control by Student’s t-test (p,0.05). (B) Uptake of [
14C]uric acid (20 mM)
by membrane vesicles was measured for 5 min at 37uC in the absence
(Control, open bar) and presence of 0.1 (gray bar) or 10 mM elacridar
(closed bar). Each bar shows the mean 6 S.E.M. (n=3–6). An asterisk (*)
shows a significant difference from uric acid uptake in the absence of
elacridar by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0030456.g003
Intestinal Secretion of Uric Acid
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player in uric acid disposition. However, in rodents, Bcrp1
expression in kidney relative to intestine and liver is reported to be
comparable [30]. Therefore, urinary excretion of uric acid was
also reduced as well as intestinal secretion in Bcrp1
2/2 mice.
Further, a compensatory mechanism may operate in Bcrp1
2/2
mice, because the SUA level should be kept constant physiolog-
ically in rodents as well as in humans. Indeed, no significant
change of SUA level was observed in mice lacking the uric acid
reabsorptive transporter Urat1 [42]. Therefore, it may not be
reasonable to evaluate the quantitative contribution of Bcrp based
only on the results in transporter-gene deficient mice.
Finally, we evaluated the intestinal secretion of uric acid in
humans using Caco-2 cells as a model of human intestinal
epithelial cells. Secretory transport of uric acid across Caco-2 cell
monolayer was greater than its absorptive transport, and such
polarized transport was abolished in the presence of elacridar,
Ko143 and MK571 (Table 3). These results imply that uric acid is
secreted into the intestine through the intestinal epithelial cells in
human as well as rat, and this process could be mediated by an
efflux transporter BCRP in human. Since MK571 and verapamil
were reported to slightly inhibit BCRP [35], uric acid transport
might be reduced by them. Unexpectedly, bidirectional transport
of uric acid was dramatically reduced in the presence of MK571,
which inhibits effectively MRP members. Although further
clarification of the mechanism should be warranted, this
observation may involve other transporters in uric acid transport
expressed in Caco-2 cells rather than BCRP, such as MRP4,
which is a putative uric acid transporter.
Our results indicate that extra-renal excretion of uric acid
amounts to at least one-fourth of urinary excretion in rats, which is
comparable with the contribution in humans, and this process
cannot be ignored in considering uric acid disposition. Further-
more, the direct intestinal secretion of uric acid was much greater
than biliary excretion, suggesting that extra-renal elimination of
uric acid mainly involves direct secretion into the gut lumen
through the intestinal epithelial cells from blood, but not through
the bile ducts. In humans, it has been reported that the uric acid
concentration in bile is 1–2 mg/dL, and biliary clearance is 0.1–
0.3 mL/min [43]. Therefore, biliary excretion of uric acid should
be a minor contributor to the extra-renal elimination pathway in
humans as well as in rats, because urinary clearance is about 5.8–
6.3 mL/min in humans [44,45]. Furthermore, it was directly
demonstrated for the first time that hBCRP/rBcrp is likely to
contribute to intestinal and biliary excretion of uric acid.
Figure 4. Plasma uric acid concentration and its intestinal and renal clearance in oxonate-treated mice. (A) Plasma uric acid
concentration, (B) intestinal clearance at the ileum, and (C) renal clearance were measured in oxonate-treated wild-type (open symbols) and Bcrp1
2/2
(closed symbols) mice by means of the intestinal closed loop method and metabolic cages. Each value indicates the mean 6 S.E.M. (n=4–5). An
asterisk (*) shows a significant difference from wild-type mice by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0030456.g004
Table 3. Transcellular transport and the effect of elacridar on
uric acid transport in Caco-2 cells.
Condition Permeability (610
26 cm/sec) Efflux ratio
AP to BL BL to AP
Control 0.8160.02 1.7360.11 2.1360.19
+2 mM elacridar 0.8660.06 0.8860.04* 1.0260.05*
+1 mM Ko143 0.8360.01 1.0760.04* 1.2660.01*
+100 mM verapamil 0.8460.05 1.2960.13 1.5560.16
+10 mM MK571 0.7360.02* 0.8160.05* 1.1160.06*
Transcellular transport of uric acid in Caco-2 monolayer was measured in the
absence or presence of elacridar (2 mM), Ko143 (1 mM), verapamil (100 mM) and
MK571 (10 mM) at 37uC and pH 7.4. The ratio was obtained by dividing BL-to-AP
permeability by AP-to-BL permeability. The values indicate mean 6 S.E.M.
(n=3). An asterisk (*) and shows a significant difference from the control by
Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0030456.t003
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hyperuricemia/gout patients by enhancing intestinal elimination
of uric acid through activation of BCRP function. It has been
reported that sevelamer, a non-absorbable hydrogel, adsorbs uric
acid nonselectively in the gastrointestinal tract, and decreases SUA
in humans [46,47]. This is consistent with the idea that the SUA
level can be controlled by enhancing secretion of uric acid into
intestinal lumen.
Materials and Methods
Chemicals and animals
[
14C]Uric acid (1.96 TBq/mol) was purchased from Moravek
Biochemicals, Inc. (Brea, CA, U.S.A.). Elacridar and potassium
oxonate were purchased from Toronto Research Chemicals
(North York, Ontario, Canada) and Kanto Chemicals (Tokyo,
Japan), respectively. All other reagents were purchased from
Sigma-Aldrich (St. Louis, MO, U.S.A.), Wako Pure Chemical
Industries, Ltd. (Osaka, Japan), Nacalai Tesque (Kyoto, Japan),
and Applied Biosystems (Foster City, CA).
All the animal studies were approved by the Committee of
Kanazawa University for the Care and Use of Laboratory Animals
and were carried out in accordance with its guideline for the Care
and Use of Laboratory Animals (AP-111937, AP-111938 and
Mm687). Six-week-old Wistar rats were purchased from Sankyo
Labo Service Corporation, Inc. (Tokyo, Japan). For the Bcrp1
2/2
mouse study, mice were obtained from Taconic Inc. (Hudson, NY).
In vivo animal study
Male Wistar rats (280630 g body weight) used in the present
study were treated with potassium oxonate, a uric acid oxidase
(uricase) inhibitor. Oxonate-treated rats were established as
described previously [34,48]. Briefly, rats were anesthetized with
50% urethane (2 mL/kg) and infused with 0.9% NaCl, 0.5%
oxonate and 4% mannitol solution from the femoral vein at the
flow rate of 3 mL/hr. As a bolus, 0.9% NaCl, 1.5% oxonate and
4% mannitol solution was administered from the jugular vein at
6 mL/kg. After equilibration for 80 min, blood, urine and bile
samples were collected at 20-min intervals. When [
14C]uric acid
(2 mCi/rat) was used, it was intravenously injected from the
jugular vein after oxonate treatment for 80 min. In order to
suppress the uricolysis of [
14C]uric acid by intestinal flora [24],
animals received orally non-absorbed antibiotics, polymyxin B,
kanamycin, and vancomycin at daily doses of 50, 50 and 20 mg/
kg, respectively, for 7 days before this animal study. Urine and bile
were collected at 20-min intervals, and blood samples were drawn
at 1, 5, 10, 20, 40, 60, 80, 100 and 120 min. Urine and bile were
collected from bladder and bile ducts, respectively, and blood from
the jugular vein. In mice, urine was collected for 24 hours by using
metabolic cages (Natsume, Tokyo, Japan).
Intestinal luminal secretion study by in situ intestinal
closed loop method
We evaluated intestinal secretion of endogenous uric acid
according to the method described previously, with some
modifications [49]. Rats were anesthetized with 50% urethane
and treated with oxonate by the same method as in the in vivo
animal study described above. Intestinal closed loops were made at
different segments: jejunum (10 cm), ileum (10 cm), and colon (3–
5 cm). Phosphate-buffered solution (PB, 0.075 M NaH2PO4 -
0.075 M Na2HPO4, pH 6.5) or inhibitor-containing PB was
injected into the intestinal loop. After 60 min, the remaining
luminal content in each loop was washed out and collected for
quantitation. Blood was obtained from the jugular vein at 1, 20, 40
and 60 min. Plasma was obtained by centrifugation and used for
quantitation.
Mice were treated with oxonate (intraperitoneal injection of
200 mg/kg oxonate in 1% arabic gum solution) at 1 hr before
injection of PB solution into the intestinal loop. Blood was
withdrawn from the jugular vein at 1, 30 and 60 min. At 60 min,
the intestinal luminal content was collected for measurement of
intestinally secreted uric acid.
The following equation was used to calculate intestinal secretory
clearance (mL/min/cm loop) and estimated total intestinal
secretory clearance (CLintestine, estimated) (mL/min):
Intestinal clearance CLintestine ðÞ ~
ALoop
AUC 0-60 ðÞ
CLintestine,estimated~
1=2|(VIleumzVJejunum)|LIleumzJejunum

z VColon|LColon ðÞ
AUC0 60
VLoop~
ALoop
60|LLoop
where A is the amount of uric acid secreted into the intestinal
lumen of each loop for 60 min, L is the length of the intestine, and
AUC is area under the plasma concentration-time curve.
Transport study in membrane vesicles
hBCRP/rBcrp, hMRP2/rMrp2, or hMDR1-expressing mem-
brane vesicles prepared from Sf9 cells were purchased from
GenoMembrane Inc. (Yokohama, Japan). Uptake experiments
were conducted as described previously [50]. Briefly, after a pre-
incubation for 5 min at 37uC, membrane vesicles (50 mg protein/
50 mL final reaction volume) were incubated for 5 min at 37uCi n
the presence of 4 mM ATP or AMP in assay buffer (1 M KCl,
1 M MgCl2, and 100 mM MOPS-Tris, pH 7.0) containing
[
14C]uric acid (1 mCi/mL). The uptake reaction was terminated
by adding 1 mL ice-cold washing buffer (1 M KCl, and 100 mM
MOPS-Tris, pH 7.0) to the membrane solution, and the mixture
was rapidly filtered through a nitrocellulose filter (0.45 mm pore
size, Millipore, Bedford, MA). The filters were washed twice with
5 mL ice-cold washing buffer. The filters were dried and dissolved
in Clearsol-I for quantitation of radioactivity.
Bidirectional trans-cellular transport study in Caco-2 cells
Caco-2 cells were obtained from the American Type Culture
Collection (Rockville, MD). Caco-2 cells were cultured in
Dulbecco’s modified Eagle’s medium (D-MEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum
(Invitrogen), 100 units/mL benzylpenicillin, 100 mg/mL strepto-
mycin, 1% (v/v) MEM non-essential amino acid solution
(Invitrogen) at 37uC under an atmosphere of 5% CO2 in air.
For bidirectional transport studies, Caco-2 cells were cultured on
Transwell filter membrane inserts (BD Falcon, surface area
0.9 cm
2 and pore size 3 mm) at a density of 6.4610
4 cells/cm
2
for 21 days before use for each experiment. Transport measure-
ment was initiated by adding transport medium (5.36 mM KCl,
136.89 mM NaCl, 0.34 mM Na2HPO4?7H2O, 0.44 mM
KH2PO4, 4.17 mM NaHCO3, 1.26 mM CaCl2, 0.49 mM
MgCl2?6H2O, 0.41 mM MgSO4?7H2O, 19.45 mM glucose,
10 mM HEPES/Tris, pH 7.4) containing [
14C]uric acid to the
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14C]uric acid to the
receiver side. Inhibitor was added to only apical side. Transport of
[
14C]uric acid was measured in two directions, namely apical (AP)-
to-basal (BL) and BL-to-AP directions. An aliquot of transport
buffer was obtained from the donor side at 5 min for measurement
of initial concentration, and from the receiver side at 30, 60, 90
and 120 min. Transport studies were performed at 37uC and
pH 7.4.
The apparent permeability (Papp, cm/sec) of [
14C]uric acid
across the cell monolayer was calculated using the following
equation:
Papp~
dQ
dt
A|Cd 0
where Q is the amount of [
14C]uric acid transported over time t.
Cd is the initial concentration in the donor side and A is the
surface area of membrane.
Real-time reverse transcription polymerase chain
reaction
Total RNA was prepared from intestinal mucosa by using
standard methods. Single-strand cDNAs were synthesized with a
High Capacity cDNA Reverse Transcription Kit (Invitrogen).
Relative quantification of rat Bcrp and rat glyceryl aldehyde 3-
phosphodehydrogenase (Gapdh) mRNA expression was per-
formed with a Real-Time PCR system (Mx3000p, Stratagene,
Cedar Creek, TX) using Brilliant SYBR Green QPCR Master
Mix and Reference Dye (Stratagene) with 35 cycles of denatur-
ation at 95uC for 15 sec, annealing at 58uC for 20 sec, and
extension at 72uC for 20 sec. The expression level was normalized
to that of rat Gapdh. The sequences of gene-specific primer pairs
were follows: forward and reverse primers for rBcrp are 59-
TTTGATAAACGGGGCACCTC-39 and 59-AGCTTTTGGA-
AGGCGAAGAG-39, respectively, and for Gapdh are 59-GGT-
GGACCTCATGGCCTACA-39 and 59-ATTGTGAGGGAGA-
TCCTCAGTGT-39, respectively.
Analytical methods
Concentrations of uric acid in plasma, urine, bile, and intestinal
content were analyzed by means of HPLC. Briefly, 80 mL 0.41%
HClO4 was added to 40 mL of sample and mixed well. The sample
was kept 4uC for 30 min. An aliquot was centrifuged at
15,000 rpm for 5 min at 4uC to separate denatured proteins.
Eighty mL of the supernatant was mixed with an equal amount of
200 mM Na2HPO4 solution, and then a portion (50 mL) was
applied to the HPLC system (Alliance 2690/UV/VIS Detector
486, Waters,Milford, MA). The HPLC analysis was performed
using Mightysil RP-18 GP 5 mm (250 mm64.6 mm, Kanto
Chemical Co. Tokyo, Japan) as an analytical column at 30uC.
The mobile phase was composed of 40 mM Na2HPO4 (pH 2.55)/
methanol (99/1), delivered at a flow rate of 1 mL/min. The
retention time was about 7.0–7.5 min. Uric acid was detected at
284 nm. The calibration curve was linear over the range of
0.25–50 mg/L.
All data are presented as the mean 6 S.E. Statistical
significance was evaluated with Student’s t-test with p,0.05 as
the criterion for a statistically significant difference.
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